It is important to note that PIONEER 3 was a larger trial than PIONEER 12 (1864 participants vs 1441 participants, respectively) and had a longer duration (78 weeks with 5 weeks of follow-up vs 26 weeks with 5 weeks of follow-up, respectively) [18]
Neurol.Sci 2010;31(1):61-64
After synthesizing the peptide chain and cleavage of the base-labile protecting groups, an efficient on-resin cyclization was performed using an excess of BOP as the coupling agent
Ozempic, which has a lower dose of 0.5-2 semaglutide, is FDA-approved for diabetes control, while higher-dose semaglutide, Wegovy, is approved for weight loss
Patients who received the 8 mg weekly dose lost 17.3% and those in the 12 mg group lost 17.5% of body weight, compared to only 1.6% in the placebo group